Nebraska Officials Split on Federal Rescheduling Amid State Rollout

Nebraska's political leaders offered mixed reactions to the Trump administration's decision Thursday to reclassify marijuana as a Schedule III controlled substance, even as the state begins implementing its own voter-approved medical cannabis program.

The federal rescheduling represents a significant shift in drug policy, moving cannabis from Schedule I—reserved for substances with no accepted medical use—to Schedule III, alongside drugs like ketamine and anabolic steroids. But Nebraska officials showed little enthusiasm for the change.

"My stance on this issue has been clear. I remain committed to combatting the growing public health and safety threat marijuana poses," one Nebraska official said in response to the rescheduling announcement.

The cautious response comes as Nebraska grapples with implementing medical marijuana legalization that voters approved in November 2024. State officials have been working through the regulatory framework needed to establish a medical cannabis program, though the process has moved slowly.

The Timing Question

The federal rescheduling arrives at a complicated moment for Nebraska. Voters passed Initiative 437 and Initiative 438 last fall, legalizing medical marijuana and establishing a regulatory commission. Yet the state has yet to issue its first cultivation or dispensary licenses.

Policy experts suggest the Schedule III designation could actually ease some implementation hurdles. Cannabis businesses in states with medical programs would gain access to standard tax deductions under Section 280E of the tax code—a change that could make Nebraska's future dispensaries more financially viable.

But state officials have shown little interest in accelerating the timeline. The Nebraska Department of Health and Human Services has indicated that regulations for the medical program won't be finalized until later this year, with dispensaries unlikely to open before 2026.

Industry Response

Cannabis advocates in Nebraska took a more optimistic view of the federal change. Industry groups pointed out that rescheduling could reduce the stigma around medical marijuana, potentially making state regulators more comfortable with implementation.

"This validates what voters already knew—marijuana has legitimate medical uses," said one advocate familiar with Nebraska's program development. "The question is whether state officials will acknowledge that reality."

The disconnect between federal policy evolution and state-level resistance reflects broader tensions in cannabis regulation. Nebraska became the 39th state to legalize medical marijuana, yet its rollout has been among the slowest in recent years.

What's Next

Nebraska's medical marijuana commission is expected to meet in the coming months to finalize licensing procedures. The state has estimated it could take 18 to 24 months from the November vote before patients can legally purchase medical cannabis.

The federal rescheduling doesn't change Nebraska's timeline directly, but it could influence how aggressively businesses pursue licenses. Cannabis companies have historically been cautious about entering states with restrictive programs and uncertain regulatory environments.

Meanwhile, the state faces ongoing legal challenges to its medical marijuana initiatives. Opponents have filed lawsuits arguing the ballot measures violated state constitutional requirements, though courts have so far allowed implementation to proceed.

For Nebraska's estimated 10,000 to 15,000 potential medical marijuana patients, the federal policy shift offers little immediate relief. Until the state completes its regulatory framework and licenses operators, they remain without legal access to cannabis medicine.

This article is based on original reporting by www.marijuanamoment.net.